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http://dx.doi.org/10.1016/j.jfma.201Kidney disease is an escalating burden all over the world. In addition to preventing kidney
injury, regenerating damaged renal tissue is as important as to retard the progression of
chronic kidney disease to end stage renal disease. Although the kidney is a delicate organ
and has only limited regenerative capacity compared to the other organs, an increasing under-
standing of renal development and renal reprogramming has kindled the prospects of regener-
ative options for kidney disease. Here, we will review the advances in the kidney regeneration
including the manipulation of renal tubular cells, fibroblasts, endothelial cells, and macro-
phages in renal disease. Several types of stem cells, such as bone marrow-derived cells,
adipocyte-derived mesenchymal stem cells, embryonic stem cells, and induced pluripotent
stem cells are also applied for renal regeneration. Endogenous or lineage reprogrammed renal
progenitor cells represent an attractive possibility for differentiation into multiple renal cell
types. Angiogenesis can ameliorate hypoxia and renal fibrosis. Based on these studies and
knowledge, we hope to innovate more reliable pharmacological or biotechnical methods for
kidney regeneration medicine.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Kidney disease and its related complications are an
important issue of public health worldwide.1e6 Thebuting authors declare no
stitute of Physiology, College
ty, 1 Jen-Ai Road, Section 1,
S.-L. Lin).
ight ª 2014, Elsevier Taiwan LLC
3.12.001incidence and prevalence of end stage renal disease (ESRD)
in Taiwan are among the highest in the world.5,6 In Taiwan,
dialysis is a heavy financial burden that consumed about 7%
of Taiwan’s annual budget for national health insurance in
2011.5 Effective strategies are urgently needed to restore
the renal function by kidney regeneration as well as to
prevent acute kidney injury (AKI) and chronic kidney dis-
ease (CKD) progression.7e13
Broadly defined, kidney regeneration includes both renal
repair and regrowth of partial or whole nephron in kidney
disease. Neonephrogenesis, the process to regenerate
every component of nephron, is a distinctive feature of& Formosan Medical Association. All rights reserved.
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the mammalian kidney.14 The reconstruction of the human
kidney is more difficult than the regeneration of any other
organ because of its complicated anatomical structure and
no neonephrogenic zone of renal tissue to form new
nephrons.15 However, many studies in kidney regeneration,
primarily from animal models, have identified methods of
renal cell modulation pharmacologically or genetically to
promote kidney regeneration.16 Stem cell or progenitor cell
therapy is also viewed as a promising strategy in regener-
ative medicine. Recent research has also identified that
restoring the renal microvasculature might be effective in
repairing the structure of diseased kidney.17 In this review,
we will describe the mechanisms of kidney regeneration
and recent progress in different strategies of regenerative
nephrology (Fig. 1).Mechanisms of kidney regeneration
The nephron is the functional unit of kidney and there are
almost one million nephrons in each adult kidney. The
essential components of the nephron include the glomer-
ulus, proximal tubule, loop of Henle, distal tubule, and
collecting duct. The nephron is also encircled by abundant
blood vessels.18 A variety of kidney diseases result in injury
of different cell types including podocytes, tubular
epithelial cells, mesangial cells, or endothelial cells.
Although the sublethal injury impairs renal function at
various degrees, it also activates the mechanisms respon-
sible for the regeneration of injured kidney tissues.18
According to current studies, there are four key pro-
cesses of kidney regeneration, including reprogramming of
endogenous renal cell, migration of bone marrow-derived
cell (BMDC) and macrophage into kidney, renal progenitor
cell differentiation, and neoangiogenesis. Growing evi-
dence has shown that the regeneration process is similar to
renal development through cell dedifferentiation. The
genes vital during nephrogenesis may regulate cellular
regeneration and tissue repair following injury in adult
kidney.19,20 In kidney following ischemiaereperfusion injury
(IRI), the surviving tubular epithelial cells recapitulate an
immature mesenchymal phenotype with re-expression of
vimentin and Pax2, a process of dedifferentiation alsoFigure 1 Regenerative approaches to renal disease.termed as reprogramming.21e23 The dedifferentiated cells
regain the ability to proliferate and repopulate the
denuded area. In addition, BMDCs migrate to the kidney
after kidney injury and can inhibit renal cells apoptosis by
an anti-inflammation effect and enhance renal cell prolif-
eration.24,25 Macrophages may scavenge the dead tissues in
acute phase and promote regeneration of tubular epithelial
cells during repair.24e26 Different renal progenitor cells,
either from local residence or recruited from circulation,
have the potential to differentiate into target cells and
promote surviving renal cell proliferation and kidney repair
after injury.16 Neoangiogenesis is stimulated through
vascular growth factors and endothelial progenitor cells
(EPCs), and can ameliorate oxidative stress and reduce
nephron loss.19Cells involved in kidney regeneration
Many cells are involved in kidney regeneration. First,
injured proximal tubular epithelial cells can dedifferentiate
and proliferate.21 Using genetic fate-mapping techniques,
Humphreys et al18 indicated that the intrinsic, surviving
tubular epithelial cells is the predominant source of new
cells in repair of the postischemic nephron. Second, distal
tubular cells can release growth factors such as epidermal
growth factor (EGF), insulin-like growth factor-1 (IGF-1),
hepatocyte growth factor (HGF), and these reparative
growth factors then act on receptors in the proximal
tubular epithelial cells to promote regeneration via para-
crine effect.27 Third, wound-healing or proreparative
macrophages can produce a variety of growth factors
including Wnt7b to promote tubular epithelial cell prolif-
eration, angiogenesis, and kidney repair.24e26
Moreover, the integrity of the renal vasculature can
have a profound impact on kidney regeneration following
injury. Recent study identified that a novel developmental
gene and protein, SCUBE1, is expressed in endothelial
cells. In vitro, suppression of SCUBE1 can inhibit the pro-
liferation of tubular epithelial cells.28 Normal kidney per-
icytes can maintain the stability of microcirculation.29
Although sustained activation of pericytes/perivascular
fibroblasts promotes kidney fibrosis, transient activation of
pericytes surrounding damaged tubules might be a normal
repair process and beneficial to functional recovery after
AKI.8,30 Renal fibroblasts produce cytokines such as fibro-
blast growth factors-1 and -7 to stimulate proliferation of
renal tubular epithelial cells, supporting the beneficial
role of activated pericytes during kidney repair after
AKI.31 In addition, replacement of renal tubular epithelial
cells cannot occur unless the reconstitution and stabili-
zation of the tissue structure because surviving tubular
epithelial cells need collagen framework to support their
proliferation and migration to repopulate the denuded
area.31Reprogramming the kidney: a novel strategy
for kidney regeneration
Cell reprogramming is defined as a switch in gene expres-
sion of one kind of cell to that of another cell type.32
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cell to a prior differentiative and pluripotent state, but also
conversion between two unrelated differentiated cell types
that does not involve a pluripotent intermediate state
(termed lineage reprogramming or transdifferentiation).33
This concept was introduced by Conrad Waddington 50
years ago and has been widely used in stem cell and renal
progenitor cell therapy in kidney regeneration.33 Recently,
studies have found more factors to modulate cell reprog-
ramming. Takahashi and Yamanaka34 demonstrated that
pluripotent stem cells can be directly generated from
fibroblast cultures by the addition of only four factors,
Oct3/4, Sox2, c-Myc, and Klf4. This technique has been
applied to many organ regeneration as well as kidney dis-
ease. For example, recent research succeeded in genera-
tion of induced pluripotent stem cells from human kidney
mesangial cells and from a renal epithelial cells shed into
the urine.35,36 Nevertheless, how to manipulate these stem
cells or progenitor cell to regenerate the renal cells is still a
big challenge (Fig. 2).
Stem cell-based therapy
Stem cells are multipotent and can divide and differen-
tiate into diverse specialized cell types. They can also self-
renew to produce more stem cells. The research of stem
cell therapy involves induction of repair using exogenous
or endogenous stem cells or the reprogramming of the
organ to reinitiate development. Here, we discuss the
research of stem cells including BMDCs, autologous
adipose-derived mesenchymal stem cells (ADMSCs), em-
bryonic stem (ES) cells, induced pluripotent stem (iPS)Figure 2 The application of reprogramming to the kidney. (A) Re
pluripotent stem cells (iPS cells)/embryonic stem cells (ES cells) to
adult cell type. (B) Lineage reprogramming induces dedifferentia
(C) Adult kidney cells or any other available adult cell type may tr
pluripotent intermediate state.34cells, and renal stem/progenitor cells for the repair of
damaged renal tissue.
BMDCs
The bone marrow contains two major populations of stem
cells, hematopoietic stem cells (HSCs), and mesenchymal
stromal cells, which provide stromal support for HSCs.
Stem cells from bone marrow have long been known for
the repair of other organs.37 Several studies have shown
that BMDCs can engraft into the kidney and participate in
normal tubular epithelial cell turnover and repair after
AKI.38 The evidence is based on the presence of Y-chro-
mosome-positive renal tubular epithelial cells in kidneys
of male recipients who received a renal transplant from a
female donor, and accounted for < 1% of the tubular
epithelial cells.39,40 Other investigators have demon-
strated elegantly that there is no evidence of differen-
tiation of BMDCs into tubular epithelial cells of the
kidney, even though postischemic functional renal
impairment was reduced by intravenous injection of bone
marrow mesenchymal stromal cells.40 Although intrave-
nous injection of HSCs could be recruited to the injured
kidney and expressed markers consistent with endothelial
progenitors at an extremely low level, repair of the kid-
ney microvasculature, tubular epithelial cells, and func-
tional recovery after IRI could be enhanced by paracrine
mechanisms rather than replacement of vasculature or
tubular epithelial cells.8 Based on this evidence, we can
suggest that rather than replacement of the injured
epithelial and endothelial cells, the major contribution of
BMDCs for renal repair is by paracrine mechanism. Takingprogramming involves the stepwise differentiation of induced
a renal lineage. The iPS cells may be derived from any other
tion of differentiated cells to specific renal progenitor cells.
ansdifferentiate to desired cell type without involvement of a
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ameliorate the injury either by directly inhibiting cell
apoptosis and preventing inflammatory cell influx. During
the repair phase, BMDCs secrete factors that
promote tubular epithelial cell dedifferentiation and
proliferation.
BMDCs also contribute to glomerular regeneration. A
small number of donor-bone marrow-derived mesangial and
endothelial cells were identified in an anti-Thy-1.1-
glomerulonephritis model.41e43 BMDCs can also differen-
tiate into podocytes and mesangial cells for the turnover of
glomeruli and ameliorate glomerular defects in Alport
syndrome model.39
ADMSCs
ADMSCs are an attractive source of stem cells with regen-
erative properties that are similar to those of BMDCs.
ADMSCs have the capacity to differentiate into other cell
types such as adipocytes, myocytes, osteoblasts, and neu-
rons.44 ADMSCs have the advantages of minimal invasive-
ness of harvesting and plentiful supply from culturing.
These cells have no ethical problem regarding the source
and less concern about safety of allo- and xenografting.
Most importantly, ADMSCs have more potent anti-
inflammatory and immunomodulating functions than
BDMCs.44 Some studies have demonstrated that ADMSCs can
reduce the severity of IRI and prevent progression of renal
fibrosis after injury through suppressing oxidative stress and
inflammatory response.44,45
ES cells
ES cells were initially derived from the inner cell mass of
the blastocyst of mouse embryos.43 These cells have the
ability to differentiate into several cell types of the
mesodermal, endodermal, and ectodermal lineages.
Therefore, they have the potential to be used as an
effective tool for kidney regenerative therapy. It has been
shown that mouse Wnt4 transfected-ES cells can differen-
tiate into tubule-like structures that express aquaporin-2
both in vitro and in vivo, and the expression of
aquaporin-2 was enhanced in the presence of HGF and
activin A.46 Steenhard et al47 injected ES cells into Day
12e13 embryonic metanephroi and then placed these in
Transwell organ culture. These ES cells differentiated into
renal epithelial structures that resembled tubules with an
efficiency approaching 50%. In addition, Kim and Dressler48
also demonstrated that ES cells injected into a developing
metanephros can be induced to differentiate to tubular
epithelia with almost 100% efficiency by using a combina-
tion of retinoic acid, activin-A, and bone morphogenetic
protein-7. However, a concern about this technique is that
in addition to producing renal cells, ES cells can develop
teratoma 14 days and 28 days after transplantation into
mouse, as demonstrated by Yamamoto et al.49 There are
also many legal and ethical issues associated with ES cell
use. Overall ES cells are a valuable cellular source for
investigating the mechanism of kidney regeneration, but
there are still many limitations for clinical applied regen-
eration therapy.iPS cells
iPS cells, able to develop into all types of cells in the body,
were first discovered by Takahashi and Yamanaka34 in 2006
who reprogrammed human fibroblasts to become pluripo-
tent stem cells by introducing four genes. These ground-
breaking discoveries have completely changed our view of
the development and cellular specialization. The Nobel
Prize in Physiology or Medicine 2012 was awarded to Dr
Yamanaka for this outstanding achievement. The following
studies also generated pluripotent stem cells from adult
mouse liver and stomach cells.50 Nevertheless, not all adult
cells can be similarly reprogrammed, suggesting that crit-
ical factors for reprogramming are cell-dependent. In
addition to established Oct4, Sox2, Klf4, and c-Myc factors,
reprogramming of mature B cells from adult spleen to iPS
cells required an additional factor, C/EBPa.51 There are
some advantages of iPS cells in kidney regeneration medi-
cine such as no ethical issues and no immune rejection
when compared to ES cells, but the risk associated with iPS
cells concerns us because Klf4 and c-Myc are oncogenic
factors. In fact, recent investigation showed that oncogenic
risk associated with iPS cells, generated from human renal
proximal tubular cells can be decreased by expression only
two transcription factors: Oct4 and Sox2.36 However, there
are still many disadvantages for iPS cells-based therapy
such as no established differentiation protocols for moving
from pluripotent state to functional kidney cell, undefined
optimal final culture conditions for target cell, and multiple
steps each requiring different factors to induce a stepwise
differentiation.23 Moreover, some cells differentiated from
iPS cells can express abnormal gene and induce T-cell-
dependent immune response in syngeneic recipients.52
Therefore, the immunogenicity of therapeutically valu-
able cells derived from patient-specific iPS cells should be
evaluated prior to when they can be used in a clinical
application.Renal progenitor cells
Multipotent adult stem cells that are important for the
turnover of the skin, bone marrow, stomach, intestine, and
cornea have been known for a long time.53 However, no
definitive evidence to date establishes the existence of a
pluripotent, self-renewing cell population in the adult
kidney. During kidney development, condensed mesen-
chyme around the tips of the branching ureteric bud con-
tains self-renewing cells capable of generating all other
elements of the nephrons, interstitium, and vasculature via
an initial mesenchymeeepithelial transition event.54 The
cells of condensed mesenchyme are regarded as the renal
stem cell population. Endowment of new nephron in
humans is complete by Week 36 of gestation,55 whereas it
continues for 1e2 weeks after birth in the mouse and the
rat. Hartman et al56 reported that stem cells of condensed
mesenchyme ceased asymmetric division and self-renewal
and then exhibited spontaneous commitment to mesen-
chymeeepithelial transition. These cells were exhausted
prior to the perinatal stage.56 This suggests that complete
regeneration involving a complete replacement of the
nephron lost does not occur in the mammalian kidney.
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cell-like pluripotent cells in adult kidney, which are called
renal progenitor cells.57 In contrast to the stem cells, renal
progenitor cells can only differentiate to some particular
cellular lineage and display no or only limited self-renewal
potential.58
Renal progenitors are identified by cell marker CD133
and CD24. CD133 is a marker of several types of adult tissue
stem cells.59 CD24 is a surface molecule that is expressed in
human metanephric mesenchyme.60 In the adult mamma-
lian nephron, renal progenitor cells gather at the urinary
pole and disperse over the Bowman capsule, the proximal
tubule, the thick ascending lim, b and the distal convoluted
tubule at the point of connection with the ureter.57,61 Renal
progenitor cells at the urinary pole can differentiate into
glomerular as well as tubular epithelial cells. Tubular pro-
genitor cells represent 2e6% of all tubular epithelial cells in
healthy adult kidneys and express CD133 and CD24, as well
vimentin, cytokeratin 7 and 19, Pax2, and nestin that are
not expressed by differentiated tubular epithelial cells.51
Glomerular progenitor cells localize within the Bowman
capsule and can differentiate toward the podocyte
phenotype. Tubular progenitor cells cannot express CD106,
whereas glomerular progenitor cells can express this sur-
face marker.51 The elegant study by Lee et al57 isolated
mouse kidney progenitor cells from the interstitium of
medulla and papilla which can differentiate to endothelial
cell and tubular epithelial cell. Treatment with mouse
kidney progenitor cells can reduce the mortality in mice
after ischemic injury. Regarding glomerular injury, Ronconi
et al62 reported that CD133þ CD24þ cells can replace
podocytes and improve chronic glomerular damage in
adriamycin-induced nephropathy.
Renal progenitor cells have higher resistance to injury in
comparison to all other differentiated cells of the kidney.
When injected in severe combined immunodeficient mice
affected by rhabdomyolysis-induced AKI, both of these
populations displayed the capacity to integrate into the
tubules, generate novel tubular epithelial cells, and improve
renal function.63 The perivascular site has also been a
reserve of progenitor cells. These cells express markers of
both pericytes and mesenchymal stem cells that are able to
proliferate in response to focal injury and promote tissue
repair.64 It is an attractive strategy that if renal progenitor
cells can also be induced via lineage-instructive reprog-
ramming or differentiated from extrarenal stem cells such as
mesenchymal stem cells, ES cells, and iPS cells. However,
achieving this exact state of differentiation in vitro has not
been proven successfully.65 These exogenous renal progen-
itor cells may enhance renal repair in addition to a small
population of endogenous renal progenitor cells.
Because stem cells cannot be manipulated easily to
differentiate to desired renal cells, less potency but reli-
able differentiation process makes renal progenitor cells
more applicable in kidney regeneration medicine.
Compared to stem cells, renal progenitor cells have ad-
vantages, such as that knowledge of intermediate cell
culture conditions is not required and renal progenitor cells
can transit directly from one phenotype into another.
However, a reliable method of inducing extra renal stem
cells to differentiate into renal progenitor cells has not
been established at this time.23Signaling pathways in mediating the
regenerative process
Convergent evidence has shown that many cells are
involved in kidney regeneration, including endogenous
renal tubular epithelial cells, macrophages, fibroblasts,
BMDCs, and renal progenitor cells. How these cells interact
with each other and what factors influence the cells to
involve in the regenerative process after renal injury re-
mains uncertain. We also need more additional research to
identify the factors in specific signaling pathways involved
in kidney regeneration and try to find novel therapeutic
interventions for this serious disease.
PI3K/AKT/mTOR pathway
It has long been observed that growth factors such as EGF,
HGF, and IGF-1 can accelerate recovery of renal function
after AKI.66 These growth factors activate a lipid kinase
(phosphotidyl-inositol-3-kinase, PI3K) that phosphorylates
phosphotidylinositol-4,5-bisphosphate to yield phosphoti-
dylinositol-3,4,5-trisphosphate. The latter phosphorylates
and activates Akt. Once activated, Akt stimulates
mammalian target of rapamycin (mTOR) by regulating the
activity of intermediary kinases. The activation of mTOR
leads to phosphorylation of downstream substrates and
then induced cell regeneration. Lieberthal et al67 demon-
strated that inhibition of mTOR by rapamycin substantially
delays recovery of renal function. Akt may inactivate some
proapoptotic factors such as Bcl-2-associated death pro-
moter, procaspase-9 and forkhead family transcription
factors. Akt also activates antiapoptotic genes.68 Deletion
of the EGF receptor in renal proximal tubular epithelial
cells impairs phosphotidyl-inositol-3-kinase/Akt signaling
and delay recovery from AKI.69
MAPK/ERK pathway
Mitogen activated protein kinases (MAPKs) is a family of
kinases that have been commonly studied on the kidney
disease. There are four different MAPK pathways in
mammalian cells: extracellular signal-regulated kinase-1
and -2 (ERK1/2), c-Jun N-terminal kinase (JNK), p38MAPK,
and extracellular signal-regulated kinase-5 (ERK5).70,71 ERK
is mainly activated by mitogenic stimuli such as growth
factors and ERK1/2 pathway has been widely investigated
in kidney regeneration. In vitro, ERK pathway activation
could enhance renal epithelial cell survival during oxidative
injury.72 Activation of the signal transducer and activator of
transcription-3 (STAT3) during oxidative stress can atten-
uate EGF receptor-mediated ERK activation and renal
tubular cell survival.73 In vivo, inhibition of ERK pathway
reduces kidney regeneration in rats with myoglobinuric
AKI.74
JAK/STAT pathway
When a growth factor such as EGF binds to the EGF re-
ceptor, Janus-activated kinase (JAK) is activated and
phosphorylates the intracellular domain of the receptor
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Through the activation of JAK/STAT pathway,
erythropoiesis-stimulating proteins suppress renal tubular
cell apoptosis in vitro and enhance renal recovery in
cisplatin-induced AKI.75 Contrary to the positive role in the
aforementioned study, inhibition of the JAK/STAT pathway
can decrease tubular epithelial cell apoptosis and kidney
inflammation in murine AKI.76 Therefore more studies are
required to clarify the effect of JAK/STAT pathway on renal
repair.
Wnt-GSK3-b-catenin pathway
The Wnts are a family of secreted and glycosylated protein
ligands. Wnt signals can inhibit glycogen synthase kinase 3
(GSK3) by phosphorylation. When GSK3 is inhibited, b-cat-
enin is stabilized and translocates into the nucleus to act as
a transcriptional coactivator of the T-cell factor/lymphoid
enhancer-binding factor family of transcription factors, and
drive the expression of its target genes.77 This pathway is
involved in the regulation of cell fate, protein synthesis,
glycogen metabolism, cell mobility, proliferation, and sur-
vival.78 Wnt pathway responses are induced in the kidney
following acute injury.24 Genetic inactivation of Wnt
signaling has been shown to impair kidney regeneration and
renal function recovery. Among the increased Wnt ligands
in the kidney after injury, macrophage-derived Wnt7b has
been shown to promote tubular epithelial cell regeneration
and kidney repair.24 In the downstream of Wnt signaling,
GSK3 is normally inhibited by Wnt ligands, as well as by
many other proliferative, prosurvival signals that increase
serine9 phosphorylation, such as IGF, EGF, and fibroblast
growth factors 16,19, and 23.79 In AKI, GSK3 can promote
the systemic inflammatory response and participates in a
number of apoptotic signaling pathways by phosphorylating
transcription factors that regulate apoptosis.80 TDZD-8, a
GSK3b inhibitor, can inactivate ischemia-induced activation
of GSK3, Bax, and caspase 3; ameliorate tubular epithelial
cell apoptosis; and significantly protect renal function.81
Expression of b-catenin can be induced in AKI and renal
tubule-specific knockout of endogenous b-catenin aggra-
vates AKI in mice.82 Another study reported that inhibition
of GSK3b can ameliorate nonsteroidal anti-inflammatory
drug-induced AKI.83 Taken together, activation of the
Wnt-GSK3-b-catenin pathway is beneficial for many kidney
disease and GSK3 inhibitor can be a target of therapeutic
agents in the future.
Angiogenesis and kidney regeneration
Vasculature integrity is essential for kidney regeneration
and attenuation of renal dysfunction, especially in CKD. No
matter what etiologies induce CKD, the common pathway is
progressive loss of the renal microvasculature, which leads
to tissue hypoxia and inflammation, further fibrotic change,
and nephron loss. Tissue fibrosis resulted in further rare-
faction and this vicious cycle cause irretrievable renal
function deterioration.8,84,85 In a normal kidney, an equi-
librium exists between proangiogenic and antiangiogenic
molecules, but an imbalance of angiogenesis-related fac-
tors is noted in the progression of CKD.29,85e87 Vascularendothelial growth factor, a proangiogenetic factor, can
reduce fibrosis and stabilize renal function in the remnant
kidney model of progressive renal failure.88 However, dys-
angiogenic isoform of vascular endothelial growth factor
became dominant in fibrotic kidneys induced by unilateral
ureteral obstruction or IRI might play a role in microvas-
cular rarefaction.85 Angiopoietin-1 gene therapy using
adenoviral vector resulted in the reduction in albuminuria,
suppression of mesangial expansion and podocyte injuries
accompanied by reduced macrophage infiltration and
attenuation of chemokines and adhesion molecules in dia-
betic nephropathy model.89 By contrast, elevated plasma
levels of angiopoietin-2 are associated with cardiovascular
disease in CKD patients and might also play a role in CKD
progression.90,91 How these angiogenic growth factors are
involved in the kidney regeneration needs further study.
The EPCs have been shown to participate in reconstructing
the microvessels of the interstitium and glomeruli.92 In
mice with adriamycin-induced nephropathy, systemically
injected EPCs homed to areas of injury and inflammation in
the kidney, a maneuver that improved renal function,
reduced proteinuria, improved vascular density, and
reduced apoptosis.93 The restoration and extension of
microvasculature is a key potential target for therapies to
heal the diseased kidney.
Bioengineered kidney
Because there are numerous ESRD patients under dialysis
and a shortage of kidney donors, recent studies have
investigated the possibility of bioengineered kidney. Pre-
vious study designed hemofiltration devices equipped with
bioengineered renal tubules that can replace renal function
in uremic dogs and temporarily improved renal function in
patients with acute renal failure.94,95 Further research at-
tempts to invent a bioengineered kidney that have the
kidney’s architecture and function and permit perfusion,
filtration, secretion, absorption, and drainage of urine.96
They decellularized rat cadaveric kidney by detergent
perfusion and yielded acellular scaffolds with vascular,
cortical, and medullary architecture, a collecting system,
and ureters. Then they seeded rat kidney scaffolds with
epithelial and endothelial cells. After several days in organ
culture, regenerated kidney constructs produced urine
in vitro. When transplanted in an orthotopic position in rat,
the grafts were perfused by the recipient’s circulation and
produced urine in vivo. Although regenerated kidney can
only replace partial renal function, this technique is still a
landmark of kidney regeneration medicine.
Future challenges and perspectives
Although there are many exciting approaches for kidney
regeneration medicine, many hurdles remain. In the future,
we should characterize gene expression profiles of regen-
eration associated cells and elucidate corresponding
signaling molecules more clearly. Based on the knowledge
of renal development, a more reliable method is needed for
the manipulation of stem cell and progenitor cell therapy.
Enhanced understanding of the mechanism of current
available drugs with the capacity of renoprotection may
Stem cells and kidney regeneration 207also help us to find the novel pathway for kidney regener-
ation and more specific pharmacologic or gene therapy
should be discovered for different renal disease. Of note,
bioengineered kidney is an important research field
because it offers resolution for the ESRD patient awaiting a
donor kidney.
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